Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.
Nathan Bahary, MD, PhD
Advertisement
Articles by Nathan Bahary, MD, PhD
Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.
Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.
Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated CholangiocarcinomaPublished: January 5th 2021 | Updated:
Dr. Bahary on the Prognosis of BRAF-Mutant Colorectal CancerPublished: October 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5